Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Multiple Myeloma 11Recurrence 8Lymphoma, Large B-Cell, Diffuse 6Sezary Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Leukemia 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × Panobinostat × Clear all
NCT00985946 2019-12-09

Study of Panobinostat in Patients With Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 2 Terminated
15 enrolled 11 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡